UNION CITY, Calif., Nov. 12, 2010 /PRNewswire/ — Abaxis, Inc.
(Nasdaq:
ABAX), a medical products company manufacturing point-of-care
blood analysis systems, today announced the release of a new
Piccolo® reagent disc panel called BioChemistry Panel Plus.
This new reagent disc will be used by healthcare professionals in
conjunction with the Piccolo Xpress™ point-of-care analyzer.
As a result of this new panel configuration, U.S. healthcare
professionals can now conduct on-site chemistry analysis in less
than 12 minutes for general inflammation and infection in
combination with comprehensive liver and kidney function
diagnostics.
The new BioChemistry Panel Plus contains the C-Reactive Protein
(CRP) assay that received 510(k) clearance in late January 2010.
In addition to CRP, the BioChemistry Panel Plus contains the
following test configuration: ALB, ALP, ALT, AMY, AST, BUN, Ca,
CRE, GGT, GLU, TP, UA. This configuration encompasses a broad
spectrum of internal organ diagnostics including liver, kidney,
pancreas and metabolic functions.
The BioChemistry Panel Plus is likely to be useful for practices
that are interested in the detection, monitoring and treatment of
diseases with inflammation or infection disorders. The new panel
may also have broad applications in the European and Asia Pacific
markets, where CRP is widely used as a standard test in general
health screenings and as part of routine clinical practice.
“The addition of the new BioChemistry Panel Plus is a testament
to our commitment to continued innovation in medical diagnostics,”
said Clint Severson, chairman and chief executive officer of
Abaxis, Inc. “We look forward to continuing to raise the bar on
diagnostic technologies that allow physicians to better care for
their patients, improve the efficiencies of their practices and
reduce the overall cost of healthcare, while increasing
‘/>”/>
SOURCE